---
title: Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
nct_id: NCT05247268
overall_status: RECRUITING
phase: PHASE2
sponsor: Fudan University
study_type: INTERVENTIONAL
primary_condition: Endometrial Neoplasm Malignant Stage I
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05247268.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05247268"
ct_last_update_post_date: 2025-04-06
last_seen_at: "2026-05-12T06:04:02.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

**Official Title:** Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer

**NCT ID:** [NCT05247268](https://clinicaltrials.gov/study/NCT05247268)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 104
- **Lead Sponsor:** Fudan University
- **Collaborators:** Peking Union Medical College Hospital
- **Conditions:** Endometrial Neoplasm Malignant Stage I
- **Start Date:** 2022-03-11
- **Completion Date:** 2027-09-10
- **CT.gov Last Update:** 2025-04-06

## Brief Summary

To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.

## Detailed Description

This will be a multicenter randomized controlled study to evaluate the treatment effects and adverse events of GnRHa plus AIs compared with MA/MPA in primary EEC patients.In this study, young patients (18-45 years) diagnosed as EEC for the first time seeking for fertility preserving treatment at the Obstetrics and Gynecology Hospital of Fudan University were screened. Patients were randomly assigned (1:1) to GnRHa+letrozole group (triprorelin acetate, intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses. letrozole, 2.5mg oral daily and no more than 24 weeks) or MA/MPA group (160 mg oral MA daily or 500 mg oral MPA daily).

Hysteroscopy will be performed every 3 months during treatment to evaluate the treatment effects. For patients with EEC, complete response (CR) is defined as the reversion of endometrial carcinoma to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia with or without atypia; Stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the progression of endometrial lesions. Continuous therapies will be needed in PR, SD or PD.The primary endpoint was cumulative complete response (CR) rate at 16 weeks of treatment. The secondary endpoints were cumulative CR rate at 28weeks of treatment, adverse events, recurrent rate, pregnancy rate, effects on ovarian function and quality of life of patients.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Consent informed and signed
* Primarily have a confirmed diagnosis of early-stage endometrial cancer (endometrioid, grade I, without myometrial inva- sion) ) based upon endometrial biopsy, diagnostic curettage or hysteroscopy
* No signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS)
* Have a strong desire for remaining reproductive function or uterus
* Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time

Exclusion Criteria:

* Pathologically confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine metastasis
* Recurrent endometrial cancer
* Combined with severe medical disease or severely impaired liver and kidney function
* Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone- dependent tumors that cannot be used with progesterone
* Those who require hysterectomy or other methods other than conservative treatment with drugs
* Known or suspected pregnancy
* Contraindication for Medroxyprogesterone Acetate, Megestrol Acetate, Triprorelin Acetate, Letrozole or pregnancy
* Hormone treatment within 3 months before entering the trial;
* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
* Smoker(\>15 cigarettes a day)
```

## Arms

- **GnRHa+letrozole** (EXPERIMENTAL) — Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
- **MA/MPA** (ACTIVE_COMPARATOR) — Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.

## Interventions

- **Megestrol Acetate 160 MG Oral Tablet** (DRUG) — At a dosage of 160 mg/day
- **Medroxyprogesterone Acetate 500 MG** (DRUG) — At a dosage of 500 mg/day
- **Triprorelin Acetate** (DRUG) — Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
- **Letrozole 2.5mg** (DRUG) — At a dosage of 2.5mg/day and no more than 24 weeks

## Primary Outcomes

- **Complete response rates within 16 weeks of treatment** _(time frame: From date of treatment initiation until the date of CR, assessed up to 16 weeks.)_ — The cumulative 16-week CR rates will be calculated in two groups

## Secondary Outcomes

- **Complete response rates within 28 weeks of treatment** _(time frame: From date of treatment initiation until the date of CR, assessed up to 28 weeks.)_
- **Time to achieve complete response** _(time frame: From date of treatment initiation until the date of CR or date of hysterectomy,From date of randomization until the date of CR, assessed up to 2 years)_
- **Adverse events** _(time frame: From date of treatment initiation until the date of CR, assessed up to 2 years)_
- **Quality of life during the treatment accessed by WHOQOL-BREF** _(time frame: From date of randomization until 12 weeks after treatment is over.)_
- **Relapse rates** _(time frame: up to 2 years after the treatment for each patient)_
- **Change of AMH (anti-mullerian hormone ) serum level** _(time frame: From date of randomization until 24 weeks after treatment is over.)_
- **The rates of fertility outcomes** _(time frame: up to 2 years after the treatment for each patient)_

## Locations (1)

- Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.obstetrics and gynecology hospital, fudan university|shanghai||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05247268.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05247268*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*